Business
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its third quarter report on Monday 20 October 2025 at 08:00 am CEST (previously Thursday 23 October 2025), reflecting the company's commitment to transparency and timely communication with stakeholders regarding its ongoing performan
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its third quarter report on Monday 20 October 2025 at 08:00 am CEST (previously Thursday 23 October 2025), reflecting the company's commitment to transparency and timely communication with stakeholders regarding its ongoing performance and outlook.","length":570,"tagName":"p"},{"type":"text","content":"Today's announcement is made in response to the following developments:","length":75,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Group revenue for Q3 2025 reached SEK 7,776 M, up 21 per cent [compared to Q3 2024] at constant exchange rates (CER)[1]. This growth was driven by higher in-market performance of Sobi products, particularly for Altuvoct, Doptelet and Gamifant.","length":243,"tagName":"p"}]},{"val":[{"type":"text","content":"The adjusted EBITA margin¹,² for Q3 2025 was 47 per cent, driven primarily by lower-than-anticipated R&D spend, demonstrating disciplined cost control and accelerated effects from organisational changes implemented in Q2 2025. Realigned SG&A and R&D activities following the confirmation from the FDA on a mid-2026 review decision on the NASP biologics license application (BLA) also contributed.","length":408,"tagName":"p"}]},{"val":[{"type":"text","content":"Year-to-date revenue as of Q3 2025 was SEK 20,417 M, representing a 15 per cent increase [compared to equivalent year to date 2024] at CER¹, and year-to-date adjusted EBITA margin¹,² as of Q3 2025 was 40 per cent.","length":213,"tagName":"p"}]},{"val":[{"type":"text","content":"A revised full year outlook for 2025: Revenue is now anticipated to grow by a low double-digit percentage at CER (previously high-single digit) and adjusted EBITA margin is anticipated to be in the mid-to-high 30s per cent of revenue (previously mid-30s).","length":255,"tagName":"p"}]},{"val":[{"type":"text","content":"An impairment charge of SEK 6,612 M is recorded in Q3 2025, relating to the impairment of the product and marketing right for Vonjo. The impairment has not affected cash flow and is included in Items...